myocarditis
Young patient, viral prodrome, infarct-like chest pain, raised troponin, non-coronary ST change → exclude ACS, then CMR confirms (oedema + LGE, Lake Louise). Most cases with chest pain and preserved LVEF recover with supportive care. Risk is set by LV dysfunction, HF, sustained VT, high-grade AV block or shock → admit, HF/arrhythmia therapy, and endomyocardial biopsy when histology changes treatment (giant cell, eosinophilic, sarcoid). No routine immunosuppression. Restrict exercise until remission (≥1 month); CMR within 6 months.
Fulminant myocarditis (shock — early transfer to an MCS/biopsy centre), giant cell myocarditis (HF + VT or AV block, poor response in 1–2 weeks), ICI myocarditis (high-dose steroids within 24 h), and ACS masquerading as myocarditis.
mechanism → management
- Injury phase (days): virus or trigger → myocyte necrosis → troponin, ST change, arrhythmia
- Immune phase: T-cell and macrophage infiltration → oedema, contractile dysfunction → most resolve; persistent inflammation → inflammatory cardiomyopathy (~10% of DCM)
- Scar phase: LGE = fibrosis → substrate for monomorphic VT years later, independent of LVEF → follow-up imaging and rhythm monitoring even after recovery
- Exercise in the active phase → tachycardia-driven inflammation and arrhythmia → restriction until remission
- Steroids help where the driver is autoimmune (giant cell, eosinophilic, sarcoid, ICI) — not in viral lymphocytic myocarditis with preserved function
recognition
| presentation | clues |
|---|---|
| infarct-like chest pain (>80%) | young, often male; fever, GI or respiratory prodrome 1–2 weeks earlier; ST elevation in non-coronary distribution; troponin rise |
| heart failure | new LV dysfunction, often non-dilated early; HHV-6, giant cell, eosinophilic |
| arrhythmia | NSVT/VT (polymorphic when active, monomorphic when scarred); AV block → think sarcoid, giant cell, Lyme |
| sudden death / shock | fulminant form |
- ECG normal in ~15%; ST elevation most common, then T-wave change, conduction block, low voltage
- troponin and NT-proBNP; CRP raised in ~80% (normal doesn’t exclude)
- echo: wall motion abnormality, increased wall thickness (oedema), effusion in up to 25%
- ACS first — angiography or CT coronary angiography by pretest probability; a “normal coronaries” MI is not myocarditis until CMR says so → MINOCA
- myopericarditis (pericarditis + troponin, normal LV) → treat as acute pericarditis; perimyocarditis = new LV dysfunction → this note
causes worth naming
| cause | clue |
|---|---|
| viral (enterovirus, adenovirus, parvovirus B19, HHV-6, influenza, SARS-CoV-2) | commonest; presumed, not tested — no routine viral serology except HIV, hepatitis C, Lyme |
| vaccines (mRNA COVID-19, smallpox) | days after vaccination; good mid-term outcome |
| immune checkpoint inhibitors | first weeks of therapy (median ~30 days), combination ICI; AV block, myositis, myasthenia overlap; mortality up to ~50% |
| drugs | clozapine (0.1–5% of users), DRESS-associated hypersensitivity |
| eosinophilic | peripheral eosinophilia (absent in ~25%), EGPA, hypereosinophilic syndrome, drug hypersensitivity; LV thrombus |
| giant cell | young–middle aged, rapidly progressive HF, VT, AV block |
| sarcoid | AV block, VT, extracardiac sarcoid → CMR + FDG-PET |
| systemic autoimmune | SLE, systemic sclerosis, myositis |
| Lyme | AV block in endemic area → antibiotics, temporary pacing |
risk stratification and workup
| risk | features | disposition |
|---|---|---|
| high | HF/shock, NYHA III–IV, cardiac arrest/syncope, sustained VT/VF, high-grade AV block, LVEF <40%, extensive LGE | ICU/CCU; MDT at referral centre; consider EMB |
| intermediate | new dyspnoea, NSVT, persistent or relapsing troponin, LVEF 41–49% or WMA, preserved LVEF with LGE ≥2 segments | admit, CMR, monitor |
| low | stable or mild symptoms, LVEF ≥50%, no or minimal LGE | ward observation → discharge once troponin trends down |
flowchart TD
A[Chest pain / HF / arrhythmia<br/>+ troponin rise] --> B[ECG, echo, CXR<br/>troponin, NT-proBNP, CRP, CBC]
B --> C{ACS likely?}
C -->|yes| D[Angiography or CTCA]
C -->|no| E{High risk?<br/>shock, VT, AV block, LVEF <40%}
D -->|no culprit| E
E -->|yes| F[CCU/ICU, HF and arrhythmia therapy<br/>EMB ± CMR, referral centre]
E -->|no| G[Admit, telemetry<br/>CMR]
G --> H{CMR}
H -->|oedema + LGE| I[Definite myocarditis<br/>supportive care]
H -->|negative| J[Reconsider diagnosis]
I -->|deteriorates or no response| F
- CMR (updated Lake Louise): T2 criterion (oedema) + T1 criterion (LGE/T1 mapping) = definite; one = possible. non-ischaemic LGE (mid-wall, subepicardial, patchy) distinguishes it from subendocardial infarct
- endomyocardial biopsy: high-risk or haemodynamically unstable, or intermediate risk not responding to therapy — when histology (giant cell, eosinophilic, sarcoid, virus PCR) would change treatment; one negative biopsy doesn’t exclude giant cell (patchy)
- family history in recurrent or arrhythmic presentations — myocarditis can unmask genetic cardiomyopathy (desmoplakin, ARVC)
management
all patients
- exercise restriction until clinical remission, ≥1 month — symptoms resolved, troponin/CRP normal, ECG and CMR inflammation resolved; individualised return
- consider beta-blocker for ≥6 months, especially with troponin rise (symptoms, arrhythmia prevention)
- chest pain with pericardial involvement → NSAID + PPI and colchicine (prevents recurrence) → acute pericarditis
- no routine immunosuppression with preserved LVEF
LV dysfunction or HF
- GDMT as for HFrEF → HFrEF management; continue ≥6 months after LV recovery before considering withdrawal
- corticosteroids may be considered if LVEF impaired and refractory to HF therapy
fulminant myocarditis
- inotropes/vasopressors → cardiogenic shock; early Shock Team call and transfer to a centre with VA-ECMO and biopsy — recovery rate is high, so bridge early
- IABP reasonable as first MCS step; escalate within ~1 h if perfusion doesn’t improve
- early EMB, even on MCS; steroids for non-infectious forms
- in-hospital survival on VA-ECMO ~60–70%; transplant/LVAD if no recovery
arrhythmia and conduction
- AV block often reversible → temporary pacing; permanent pacemaker only if high-grade block persists → bradyarrhythmias and pacemakers
- sustained VT in active inflammation → treat acutely; ICD decision usually deferred 3–6 months (wearable defibrillator as bridge in high-risk patients)
- sustained poorly tolerated VT after the active phase, or sarcoid with VT or LVEF ≤35% → ICD → ventricular arrhythmias and sudden cardiac death
- giant cell or sarcoid with VT/AV block → early ICD consideration
specific forms
| form | treatment |
|---|---|
| ICI myocarditis | stop ICI (rechallenge only after MDT review); pulse IV methylprednisolone within 24 h; steroid-refractory at 24–48 h → second-line immunosuppression — doses and escalation → immune checkpoint inhibitor toxicity |
| giant cell | combined immunosuppression (steroid + cyclosporine ± azathioprine/mycophenolate); steroid alone doesn’t prolong transplant-free survival; ~85% death or transplant at 3 years historically |
| eosinophilic | IV steroids; treat cause (stop drug, EGPA, HES); consider anticoagulation (LV thrombus ~12%) |
| sarcoid | prednisone ± methotrexate; FDG-PET to monitor |
| virus-negative lymphocytic, chronic/inflammatory CM | prednisone 1 mg/kg ± azathioprine — specialist, biopsy-proven only |
| clozapine / drug | stop drug; steroids if severe |
| Lyme | doxycycline 100 mg BID PO if mild; ceftriaxone 2 g IV daily if severe; 14–21 days |
follow-up and prognosis
- at ≤6 months: clinical review, ECG, Holter, exercise test, echo and CMR → guides return to sport and work, residual risk
- uncomplicated: review at 6, 12 and 24 months; complicated or residual LGE/LV dysfunction → lifelong
- uncomplicated (chest pain, preserved LVEF): in-hospital mortality ~0%, recurrence ~5% at 1 year
- complicated: in-hospital mortality ~8.5%, death or transplant ~18% at 5 years; fulminant ~24% mortality at 60 days
- prognosis tracks LVEF at baseline and at 6 months; persistent LGE (especially septal) predicts VT regardless of LVEF
- driving after VT/ICD → fitness to drive (cardiac)
Prepared 2026-10-22. Not yet verified — check every number against the sources.